title: Rabies vaccines: where do we stand, where are we heading?
abstract: Rabies being the most lethal zoonotic, vaccine-preventable viral disease with worldwide distribution of reservoir wild animals presents unique challenges for its diagnosis, management and control. Although vaccines available are highly effective, which had played the key role in controlling rabies in North America, western Europe and in a number of Asian and Latin American countries, the requirement of multiple doses along with boosters, associated cost to reduce the incidence in wild animals and prophylactic human vaccination has remained a major impediment towards achieving the same goals in poorer parts of the world such as sub-Saharan Africa and southeast Asia. Current efforts to contain rabies worldwide are directed towards the development of more safe, cheaper and efficacious vaccines along with anti-rabies antibodies for post-exposure prophylaxis. The work presented here provides an overview of the advances made towards controlling the human rabies, particularly in last 10 years, and future perspective.
authors.affiliation: BSL3 Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi - 110067, Delhi, India.
authors.forename: Manpreet
authors.initials: M
authors.lastname: Kaur
authors.forename: Rajni
authors.initials: R
authors.lastname: Garg
authors.forename: Samer
authors.initials: S
authors.lastname: Singh
authors.forename: Rakesh
authors.initials: R
authors.lastname: Bhatnagar
mesh_terms: D055808:Drug Discovery / Q000639:trends; D014943:Global Health; D006801:Humans; D011818:Rabies / Q000453:epidemiology* / Q000517:prevention & control*; D011819:Rabies Vaccines / Q000276:immunology* / Q000302:isolation & purification*; D014611:Vaccination / Q000191:economics / Q000379:methods*
chemical_list: D011819:Rabies Vaccines
keywords: encephalitis; glycoprotein; in vivo challenge; protection; rabies virus-neutralizing antibody; survival; therapeutics; vaccines